B J Giantonio

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint The role of the Eastern Cooperative Oncology Group in establishing standards of cancer care: over 50 years of progress through clinical research
    Bruce J Giantonio
    Department of Medicine, The University of Pennsylvania School of Medicine, Philadelphia, PA 19103, USA
    Semin Oncol 35:494-506. 2008
  2. ncbi request reprint Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200
    Bruce J Giantonio
    University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 25:1539-44. 2007
  3. ncbi request reprint A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200
    B J Giantonio
    University of Pennsylvania, Philadelphia, PA 19104, USA
    Ann Oncol 17:1399-403. 2006
  4. ncbi request reprint Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly two-hour infusion in patients with advanced solid tumors
    Bruce J Giantonio
    Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 10:1282-8. 2004
  5. ncbi request reprint Effect of time interval between surgery and preoperative chemoradiotherapy with 5-fluorouracil or 5-fluorouracil and oxaliplatin on outcomes in rectal cancer
    C M Dolinsky
    Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Surg Oncol 96:207-12. 2007
  6. ncbi request reprint Superantigen-targeted therapy: phase I escalating repeat dose trial of the fusion protein PNU-214565 in patients with advanced gastrointestinal malignancies
    R K Alpaugh
    Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 4:1903-14. 1998
  7. ncbi request reprint Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group
    B J Giantonio
    University of Pennsylvania, Philadelphia, USA
    Invest New Drugs 19:89-92. 2001
  8. ncbi request reprint Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies
    Joshua H Bilenker
    Abramson Family Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
    Cancer Chemother Pharmacol 53:357-60. 2004
  9. ncbi request reprint Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase Network
    Naomi B Haas
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer 98:1837-41. 2003
  10. ncbi request reprint Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings
    Bruce J Giantonio
    Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Semin Oncol 33:S15-8. 2006

Detail Information

Publications12

  1. doi request reprint The role of the Eastern Cooperative Oncology Group in establishing standards of cancer care: over 50 years of progress through clinical research
    Bruce J Giantonio
    Department of Medicine, The University of Pennsylvania School of Medicine, Philadelphia, PA 19103, USA
    Semin Oncol 35:494-506. 2008
    ....
  2. ncbi request reprint Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200
    Bruce J Giantonio
    University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 25:1539-44. 2007
    ..This study was conducted to determine the effect of bevacizumab (at 10 mg/kg) on survival duration for oxaliplatin-based chemotherapy in patients with previously treated metastatic colorectal cancer...
  3. ncbi request reprint A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200
    B J Giantonio
    University of Pennsylvania, Philadelphia, PA 19104, USA
    Ann Oncol 17:1399-403. 2006
    ..Following a toxicity review of other trials using IFL, subsequent patients were enrolled at reduced doses of irinotecan (100 mg/m(2)) and 5-fluorouracil (400 mg/m(2))...
  4. ncbi request reprint Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly two-hour infusion in patients with advanced solid tumors
    Bruce J Giantonio
    Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 10:1282-8. 2004
    ....
  5. ncbi request reprint Effect of time interval between surgery and preoperative chemoradiotherapy with 5-fluorouracil or 5-fluorouracil and oxaliplatin on outcomes in rectal cancer
    C M Dolinsky
    Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Surg Oncol 96:207-12. 2007
    ..Preoperative chemoradiotherapy for locally advanced rectal cancer is now considered "standard of care." However, the optimal time interval for resection after neoadjuvant therapy is unknown...
  6. ncbi request reprint Superantigen-targeted therapy: phase I escalating repeat dose trial of the fusion protein PNU-214565 in patients with advanced gastrointestinal malignancies
    R K Alpaugh
    Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 4:1903-14. 1998
    ..This pharmacodynamically based dosing scheme will be tested in future repeated-dose clinical trials and will define maximally tolerated doses of this powerful new immunotherapy approach...
  7. ncbi request reprint Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group
    B J Giantonio
    University of Pennsylvania, Philadelphia, USA
    Invest New Drugs 19:89-92. 2001
    ..Any grade fever occurred in 10 patients (25.6%) and any grade chills occurred in 9 patients (23.1%). CONCLUSION: Poly ICLC at this dose and schedule is well tolerated in both patient populations and is inactive in renal carcinoma...
  8. ncbi request reprint Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies
    Joshua H Bilenker
    Abramson Family Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
    Cancer Chemother Pharmacol 53:357-60. 2004
    ..To determine the maximum tolerated dose and dose-limiting toxicities (DLTs) of ZD9331 in combination with cisplatin in patients with refractory solid tumors and to describe any preliminary antitumor activity associated with this regimen...
  9. ncbi request reprint Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase Network
    Naomi B Haas
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer 98:1837-41. 2003
    ..Estramustine has been shown to potentiate the antimicrotubule effects of vinblastine. The authors sought to increase the activity of vinblastine in RCC through the addition of estramustine...
  10. ncbi request reprint Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings
    Bruce J Giantonio
    Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Semin Oncol 33:S15-8. 2006
    ....
  11. doi request reprint Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer
    Gregory L Beatty
    Hospital of University of Pennsylvania, Division of Hematology Oncology, 16 Penn Tower, Philadelphia, PA 19104, USA
    Expert Rev Anticancer Ther 8:683-8. 2008
    ..Future research will need to focus on the mechanisms whereby bevacizumab enhances the benefit of chemotherapy to identify predictive markers that better define which patient populations will benefit the most from treatment...
  12. ncbi request reprint Gastrointestinal perforation and cancer therapy: managing risk to achieve benefit
    Bruce J Giantonio
    Onkologie 28:177-8. 2005